12:00 AM
 | 
Mar 16, 2009
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Generex Oral-lyn: Interim Phase III data

Interim data from 60 patients in the ongoing, open-label, international Phase III GEN-084-OL trial showed that Generex Oral-lyn maintained non-inferiority to standard injectable human insulin at 6 months. No significant or...

Read the full 135 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >